Strategic Shift

Business

SciDev's Turnaround Story: From Losses to Profitability as Capital Efficiency Rises

The Australian chemicals company SciDev (ASX:SDV) is showing early signs of a financial transformation, with its return on capital employed turning positive after years of losses. While its current returns still lag the industry average, a significant increase in capital deployment suggests the firm is aggressively reinvesting for growth.

Jan 30, 2026

Business

Global Sugar Glut Deepens, Sending Prices to Multi-Year Lows

Sugar futures tumbled further this week, with New York prices hitting a 2.5-month low and London white sugar sinking to a five-year trough, as analysts warn of swelling global surpluses driven by record harvests in Brazil and India.

Jan 30, 2026

Business

Ocean Network Express Posts $88 Million Q3 Loss Amid Freight Market Downturn

The global container shipping giant Ocean Network Express reported a net loss for its third fiscal quarter, citing soft demand and declining freight rates, particularly on key Asia-U.S. and Asia-Europe routes. The carrier anticipates a gradual recovery in the coming months.

Jan 30, 2026

Business

Deutsche Bank Bets Big on CoreWeave, Upgrades to 'Buy' with $140 Target Ahead of Key Report

Deutsche Bank has upgraded AI infrastructure provider CoreWeave to 'Buy,' significantly raising its price target to $140, citing a strong medium-term outlook and capacity expansion plans backed by a deepened partnership with Nvidia.

Jan 30, 2026

Business

Northland Cuts Bitdeer Price Target to $25 After December Update, Maintains Bullish Stance

Northland Capital has revised its price target for Bitdeer Technologies (BTDR) downward to $25, citing a more conservative valuation approach following the company's latest operational update. The firm, however, reaffirmed its Outperform rating, signaling continued confidence in the blockchain and high-performance computing firm's long-term strategy.

Jan 30, 2026

Business

Guggenheim Backs AtaiBeckley with Buy Rating, $11 Target, Citing Breakthrough Potential in Mental Health

Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.

Jan 30, 2026

Business

Century Therapeutics Gains Analyst Confidence with Extended Cash Runway and Key IND Submission on Horizon

Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.

Jan 30, 2026

Business

Maxim Group Reiterates Bullish Stance on Strive (ASST), Sees 50% Upside to $1.50 Target

Investment firm Maxim Group reaffirms its Buy rating and $1.50 price target for Strive Inc., following the company's transformative acquisition of Semler Scientific, which positions it as a major corporate Bitcoin holder and expands its healthcare tech footprint.

Jan 30, 2026

Business

Citi Boosts Lexicon Pharmaceuticals Outlook on Novo Nordisk Partnership Progress

Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.

Jan 30, 2026

Business

Reed Jobs Launches $200M+ Venture Fund Aiming to Turn Cancer into a Manageable Condition

Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.

Jan 30, 2026

Business

Fiserv's Plunge: A Value Trap or a Turnaround Bet for 2026?

Once a fintech stalwart, Fiserv shares have cratered 70% in a year. As its 'One Fiserv' restructuring plan kicks in, investors are grappling with whether the beaten-down stock is a bargain or a warning sign.

Jan 30, 2026

Business

Markets Brace for Warsh Era: Hawkish Past Meets Political Pressure at the Fed

President Trump's surprise nomination of former Fed Governor Kevin Warsh to lead the central bank sends mixed signals to investors, stirring debate over future monetary policy and market stability.

Jan 30, 2026

Business

Cocoa Futures Bounce from Multi-Year Lows as Oversold Market Triggers Short Covering

Cocoa prices staged a modest technical rebound on Friday, halting a month-long slide that had pushed contracts to their lowest levels in over two years. The move higher, driven by short-covering in an oversold market, comes amid a complex backdrop of abundant near-term supplies, weakening demand, and a tightening longer-term outlook.

Jan 30, 2026

Business

Bunge Shares Surge to Three-Year Peak as Agribusiness Giant Rides Market Momentum

Global agribusiness leader Bunge Ltd. (BG) reached a fresh three-year high this week, buoyed by strong technical indicators and sustained momentum in the essential food supply chain sector, even as analyst price targets remain widely dispersed.

Jan 30, 2026

Business

OpenAI's Reported 2026 IPO: A High-Stakes Test for the AI Investment Frenzy

Sources indicate OpenAI is accelerating plans for a late-2026 public listing, a move that would place its massive cash burn and long road to profitability under intense investor scrutiny, potentially defining the next phase of the AI boom.

Jan 30, 2026

Business

Bloomin' Brands Faces Headwinds: Debt, Stagnant Sales Cloud Outlook

Shares of restaurant operator Bloomin' Brands have tumbled over 35% in six months, raising questions about its financial health and growth trajectory as analysts flag significant risks.

Jan 30, 2026

Business

Analysts Sound Caution on ICF International as Backlog Shrinks, Point to Alternative Tech Play

While ICF International's stock has kept pace with the broader market, analysts highlight concerns over declining backlog and slowing revenue growth, suggesting investors may find better opportunities elsewhere.

Jan 30, 2026

Business

Therapeutics Sector Shows Resilience in Q3: United Therapeutics Lags as Halozyme and Biogen Outperform

A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.

Jan 30, 2026

World

Trump's 'Madman' Diplomacy Tests Iran's Limits as Middle East Braces for Escalation

President Trump's revival of Nixon-era 'madman theory' tactics—mixing calibrated military strikes with extreme threats—aims to force Iranian concessions without full-scale war. But as Tehran perceives an existential threat, analysts warn the high-stakes gamble risks a catastrophic miscalculation.

Jan 30, 2026

World

Immigrant Rights Groups Sue ICE Over Policy Allowing Warrantless Home Entries

A coalition of immigrant advocacy organizations has filed a federal lawsuit challenging a newly revealed ICE policy that permits agents to enter private residences without judicial warrants, arguing it violates constitutional protections against unreasonable searches.

Jan 30, 2026